Alembic Pharmaceuticals has informed the exchange that the Company has successfully completed the United States Food and Drug Administration (USFDA) inspection at its Oncology (injectable and Oral Solid) Formulation Facility at Panelav. The inspection was conducted from February 28, 2024 to March 8, 2024. The USFDA issued a Form 483 with four procedural observation.
The above information is a part of company’s filings submitted to BSE.